MedDataX Logo

Bleeding Events After Triple Antithrombotic Therapy Initiation.

NCT ID: NCT03203980

Last Updated: 2017-07-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-07-15

Study Completion Date

2018-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The optimal antithrombotic therapy for patients requiring anticoagulation after coronary stenting is unknown. Double platelets suppressive agents combined with oral anticoagulation (triple antithrombotic therapy) remains the Gold standard.

Our study aims at studying bleeding events occurring until 6 months after the initiation of triple antithrombotic therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bridging Therapy in Patients at High Risk for Stent Thrombosis Undergoing Surgery

NCT00653601

Bleeding Thrombosis
UNKNOWN

Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies

NCT03157154

Hemophilia
COMPLETED

Evaluation of Antithrombin Deficiency in Patients of Intensive Care Unit Placed on Extracorporeal Membrane Oxygenation

NCT04133844

Severe Cardiac Insufficiency
COMPLETED

Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.

NCT06066762

Heparin-induced Thrombocytopenia
UNKNOWN

Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets

NCT05627375

Venous Thromboembolic Disease
RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bleeding

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triple antithrombotic therapy

patients who are prescribed double antiplatelets agents and oral anticoagulation (except VKA)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients requiring triple antithrombotic therapy, including double antiplatelets agents and oral anticoagulation

Exclusion Criteria

* history of bleeding
* patients already under triple antithrombotic therapy
* patients under vitamin K antagonists
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Central Hospital, Nancy, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-A01733-50

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

REpetitive Assessement of SCOREs in Patients on Dual Antiplatelet Therapy
NCT03526614 COMPLETED
Early Versus Late Resumption of Anticoagulation in Patients With Both High Thrombosis Risk and Major HEmoRrhage
NCT02091479 TERMINATED PHASE3
Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
NCT02164864 COMPLETED PHASE3
Evaluation of the Interference of Antithrombotic Agents With Laboratory Monitoring of Heparin Therapy
NCT02839434 TERMINATED
Keeping Oral o Parental AnticoaguLation in the Acute Phase of Cardioembolic Ischemic Stroke
NCT05486351 UNKNOWN
Anticoagulation Regiments in Patients With Prosthetic Heart Valve Thrombosis
NCT02240953 UNKNOWN NA
The Perioperative Management of Anti-thrombotic Drug Registry
NCT03695159 COMPLETED
A Multifaceted Intervention to Improve Bleeding Management Among Patients Using Oral Anticoagulants (IMPACT-BLEEDING)
NCT06575517 WITHDRAWN
Does Thinning the Blood During Surgery Prevent Blood Clots Following Total Knee Replacement Surgery
NCT00253851 COMPLETED PHASE4
WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)
NCT00769938 COMPLETED PHASE4
3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
NCT00365950 COMPLETED PHASE4
Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus
NCT05825573 ACTIVE_NOT_RECRUITING PHASE3
Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy
NCT00625248 COMPLETED
Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome
NCT01660061 COMPLETED
Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants
NCT02185027 COMPLETED
Prevention of Thrombosis Recurrence in Patients With Low Circulating Levels of Antithrombin.
NCT01382550 UNKNOWN
Predicting Bleeding Risk on Anticoagulant Therapy for Venous Thromboembolism
NCT00788736 COMPLETED
Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia
NCT03269019 UNKNOWN
The Randomized OPTIMAL-ACT Trial
NCT03772613 COMPLETED PHASE2
Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals
NCT07276074 RECRUITING
Prevention of Venous Thrombosis After Permanent Transvenous Leads Implantation
NCT00621491 COMPLETED NA
Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients
NCT00356759 COMPLETED PHASE2
Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy
NCT03885180 UNKNOWN NA
Aspirin Thromboprophylaxis After First-line Total Hip and Knee Replacement
NCT05128214 UNKNOWN
Duloxetine - Warfarin Pharmacodynamic Study
NCT00533026 COMPLETED PHASE1